vs
Side-by-side financial comparison of MAXCYTE, INC. (MXCT) and NATIONAL RESEARCH CORP (NRC). Click either name above to swap in a different company.
NATIONAL RESEARCH CORP is the larger business by last-quarter revenue ($35.2M vs $4.8M, roughly 7.4× MAXCYTE, INC.). NATIONAL RESEARCH CORP runs the higher net margin — 5.1% vs -200.5%, a 205.6% gap on every dollar of revenue. On growth, NATIONAL RESEARCH CORP posted the faster year-over-year revenue change (-4.6% vs -20.9%). NATIONAL RESEARCH CORP produced more free cash flow last quarter ($6.1M vs $-2.9M). Over the past eight quarters, NATIONAL RESEARCH CORP's revenue compounded faster (-0.2% CAGR vs -7.4%).
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
National Research Corporation, doing business as NRC Health, is an American healthcare company which provides healthcare products and subscription-based solutions in United States and Canada. It was founded in 1981, and is based in Lincoln, Nebraska.
MXCT vs NRC — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $35.2M |
| Net Profit | $-9.6M | $1.8M |
| Gross Margin | — | — |
| Operating Margin | -234.5% | 13.3% |
| Net Margin | -200.5% | 5.1% |
| Revenue YoY | -20.9% | -4.6% |
| Net Profit YoY | 9.4% | -72.6% |
| EPS (diluted) | — | $49.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.8M | $35.2M | ||
| Q3 25 | $4.6M | $34.6M | ||
| Q2 25 | $5.8M | $34.0M | ||
| Q1 25 | $5.7M | $33.6M | ||
| Q4 24 | $6.1M | $36.9M | ||
| Q3 24 | $5.6M | $35.8M | ||
| Q2 24 | $5.0M | $35.0M | ||
| Q1 24 | $5.6M | $35.3M |
| Q4 25 | $-9.6M | $1.8M | ||
| Q3 25 | $-12.4M | $4.1M | ||
| Q2 25 | $-12.4M | $-106.0K | ||
| Q1 25 | $-10.3M | $5.8M | ||
| Q4 24 | $-10.6M | $6.6M | ||
| Q3 24 | $-11.6M | $5.7M | ||
| Q2 24 | $-9.4M | $6.2M | ||
| Q1 24 | $-9.5M | $6.4M |
| Q4 25 | -234.5% | 13.3% | ||
| Q3 25 | -307.4% | 22.4% | ||
| Q2 25 | -244.3% | 4.7% | ||
| Q1 25 | -214.1% | 25.6% | ||
| Q4 24 | -213.1% | 26.0% | ||
| Q3 24 | -250.4% | 22.3% | ||
| Q2 24 | -241.0% | 25.3% | ||
| Q1 24 | -219.8% | 24.8% |
| Q4 25 | -200.5% | 5.1% | ||
| Q3 25 | -269.7% | 11.9% | ||
| Q2 25 | -212.2% | -0.3% | ||
| Q1 25 | -178.7% | 17.2% | ||
| Q4 24 | -175.0% | 17.8% | ||
| Q3 24 | -205.9% | 15.9% | ||
| Q2 24 | -188.8% | 17.6% | ||
| Q1 24 | -170.6% | 18.0% |
| Q4 25 | — | $49.58 | ||
| Q3 25 | $-0.12 | $0.18 | ||
| Q2 25 | $-0.12 | $-0.01 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | — | $0.27 | ||
| Q3 24 | $-0.11 | $0.24 | ||
| Q2 24 | $-0.09 | $0.26 | ||
| Q1 24 | — | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.0M | $4.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.5M | $14.0M |
| Total Assets | $202.5M | $134.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $103.0M | $4.1M | ||
| Q3 25 | $105.7M | $2.2M | ||
| Q2 25 | $126.6M | $5.3M | ||
| Q1 25 | $138.3M | $2.5M | ||
| Q4 24 | $154.5M | $4.2M | ||
| Q3 24 | $153.8M | $3.5M | ||
| Q2 24 | $157.3M | $485.0K | ||
| Q1 24 | $157.5M | $1.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $48.7M | ||
| Q2 24 | — | $33.3M | ||
| Q1 24 | — | $35.2M |
| Q4 25 | $171.5M | $14.0M | ||
| Q3 25 | $180.3M | $14.3M | ||
| Q2 25 | $190.7M | $21.3M | ||
| Q1 25 | $199.4M | $29.7M | ||
| Q4 24 | $206.3M | $31.3M | ||
| Q3 24 | $213.3M | $34.6M | ||
| Q2 24 | $221.3M | $40.2M | ||
| Q1 24 | $226.4M | $36.9M |
| Q4 25 | $202.5M | $134.9M | ||
| Q3 25 | $213.5M | $135.7M | ||
| Q2 25 | $219.8M | $141.4M | ||
| Q1 25 | $230.0M | $135.2M | ||
| Q4 24 | $239.5M | $132.5M | ||
| Q3 24 | $248.6M | $131.8M | ||
| Q2 24 | $251.5M | $119.1M | ||
| Q1 24 | $257.9M | $120.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | — | 0.95× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.7M | $7.2M |
| Free Cash FlowOCF − Capex | $-2.9M | $6.1M |
| FCF MarginFCF / Revenue | -61.0% | 17.2% |
| Capex IntensityCapex / Revenue | 4.8% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 3.99× |
| TTM Free Cash FlowTrailing 4 quarters | $-36.2M | $15.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.7M | $7.2M | ||
| Q3 25 | $-7.5M | $13.8M | ||
| Q2 25 | $-9.9M | $-1.1M | ||
| Q1 25 | $-14.4M | $6.6M | ||
| Q4 24 | $-7.8M | $6.4M | ||
| Q3 24 | $-4.4M | $9.4M | ||
| Q2 24 | $-4.8M | $6.8M | ||
| Q1 24 | $-10.6M | $12.0M |
| Q4 25 | $-2.9M | $6.1M | ||
| Q3 25 | $-7.8M | $10.2M | ||
| Q2 25 | $-10.4M | $-4.1M | ||
| Q1 25 | $-15.1M | $3.7M | ||
| Q4 24 | $-8.0M | $1.9M | ||
| Q3 24 | $-4.8M | $7.8M | ||
| Q2 24 | $-5.1M | $1.5M | ||
| Q1 24 | $-11.4M | $7.9M |
| Q4 25 | -61.0% | 17.2% | ||
| Q3 25 | -168.5% | 29.4% | ||
| Q2 25 | -179.2% | -12.2% | ||
| Q1 25 | -262.3% | 10.9% | ||
| Q4 24 | -131.6% | 5.2% | ||
| Q3 24 | -85.5% | 21.8% | ||
| Q2 24 | -103.3% | 4.3% | ||
| Q1 24 | -203.6% | 22.4% |
| Q4 25 | 4.8% | 3.2% | ||
| Q3 25 | 6.5% | 10.4% | ||
| Q2 25 | 10.0% | 8.8% | ||
| Q1 25 | 11.4% | 8.9% | ||
| Q4 24 | 2.4% | 12.0% | ||
| Q3 24 | 7.2% | 4.5% | ||
| Q2 24 | 5.9% | 15.0% | ||
| Q1 24 | 14.4% | 11.7% |
| Q4 25 | — | 3.99× | ||
| Q3 25 | — | 3.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.15× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
